Early "male lumpectomy" study could boost the use of focal cryoablation therapy
This article was originally published in Clinica
Executive Summary
Potentially pushing focal cryoablation therapy into an additional US patient base of 180,000, a study has shown that the therapy can be used to successfully treat 80% of prostate cancer patients - where it is currently a niche treatment. The study, by the Celebration Health/Florida Hospital in Orlando, found that the therapy preserved potency in a majority of patients and limited incontinence problems, "without compromising cancer control". The authors claimed that the therapy will "fill the gap" between watchful waiting and "radical" whole irradiation treatments.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.